AR118585A1 - Métodos para tratar la hipertensión portopulmonar - Google Patents

Métodos para tratar la hipertensión portopulmonar

Info

Publication number
AR118585A1
AR118585A1 ARP200100942A ARP200100942A AR118585A1 AR 118585 A1 AR118585 A1 AR 118585A1 AR P200100942 A ARP200100942 A AR P200100942A AR P200100942 A ARP200100942 A AR P200100942A AR 118585 A1 AR118585 A1 AR 118585A1
Authority
AR
Argentina
Prior art keywords
methods
patient
portopulmonary hypertension
macitentan
treat
Prior art date
Application number
ARP200100942A
Other languages
English (en)
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of AR118585A1 publication Critical patent/AR118585A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5578—Eicosanoids, e.g. leukotrienes or prostaglandins having a pentalene ring system, e.g. carbacyclin, iloprost
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente proporciona métodos para tratar la hipertensión portopulmonar que comprenden administrar a un paciente que lo necesita una cantidad terapéuticamente eficaz de macitentán. Preferentemente, los métodos están probados clínicamente como seguros y/o eficaces. También se proporcionan métodos para mejorar la categoría de riesgo de mortalidad perioperatoria del trasplante de hígado, mejorar la idoneidad para la excepción de MELD y reducir el riesgo de ser eliminado de una lista de espera para trasplante de hígado en un paciente con hipertensión portopulmonar y enfermedad hepática, que comprenden administrar a un paciente que lo necesita una cantidad terapéuticamente eficaz de macitentán. Reivindicación 1: Macitentán para usar en el tratamiento de la hipertensión portopulmonar en un paciente.
ARP200100942A 2019-04-05 2020-04-03 Métodos para tratar la hipertensión portopulmonar AR118585A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962830008P 2019-04-05 2019-04-05

Publications (1)

Publication Number Publication Date
AR118585A1 true AR118585A1 (es) 2021-10-20

Family

ID=70189952

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200100942A AR118585A1 (es) 2019-04-05 2020-04-03 Métodos para tratar la hipertensión portopulmonar

Country Status (11)

Country Link
US (1) US20220257595A1 (es)
EP (1) EP3946347A1 (es)
JP (1) JP2022527210A (es)
CN (1) CN113795257A (es)
AR (1) AR118585A1 (es)
AU (1) AU2020252263A1 (es)
CA (1) CA3132171A1 (es)
IL (1) IL286949A (es)
MA (1) MA55507A (es)
TW (1) TW202103703A (es)
WO (1) WO2020201479A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113194953A (zh) 2018-12-21 2021-07-30 埃科特莱茵药品有限公司 用于治疗肺动脉高血压的药物组合物
TW202042818A (zh) 2019-01-25 2020-12-01 瑞士商艾克泰聯製藥有限公司 用於治療慢性血栓性肺高血壓之醫藥組成物
WO2023038600A1 (en) * 2021-09-07 2023-03-16 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi A capsule formulation comprising macitentan

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0116237B8 (pt) 2000-12-18 2021-05-25 Actelion Pharmaceuticals Ltd "composto de sulfamida, composição farmacêutica contendo o mesmo e seu uso como medicamento antagonista de receptor de endotelina".
WO2013130119A1 (en) * 2012-02-29 2013-09-06 Gilead Sciences, Inc. Method for treating a pulmonary hypertension condition without companion diagnosis
CN104411691B (zh) * 2013-06-14 2016-05-25 杭州普晒医药科技有限公司 马西替坦晶体及其制备方法、其药物组合物和用途

Also Published As

Publication number Publication date
CN113795257A (zh) 2021-12-14
US20220257595A1 (en) 2022-08-18
AU2020252263A1 (en) 2021-12-02
JP2022527210A (ja) 2022-05-31
CA3132171A1 (en) 2020-10-08
MA55507A (fr) 2022-05-11
TW202103703A (zh) 2021-02-01
WO2020201479A1 (en) 2020-10-08
IL286949A (en) 2021-12-01
EP3946347A1 (en) 2022-02-09

Similar Documents

Publication Publication Date Title
ECSP17072756A (es) Terapia de combinación del receptor del factor de crecimiento de fibroblastos (fgfr)/muerte programada 1 (pd-1) para el tratamiento del cáncer.
CL2022002808A1 (es) Inhibidores de kif18a para el tratamiento de enfermedades neoplásicas
AR118585A1 (es) Métodos para tratar la hipertensión portopulmonar
CO2019007810A2 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer
UY38263A (es) Compuestos de purinona y su uso en el tratamiento del cáncer
GT201400166A (es) Miméticos de apelina sintéticos para el tratamiento de insuficiencia cardiaca
CO2017004715A2 (es) Métodos y formulaciones para tratar enfermedades vasculares de los ojos
CL2017001117A1 (es) Métodos para tratar enfermedades oculares.
PE20191407A1 (es) Uso de gaboxadol en el tratamiento de tinnitus
BR112022008641A2 (pt) Métodos de tratamento com modulador de miosina
ECSP20046463A (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas
CR20190468A (es) Métodos para tratar enfermedades y trastornos mediados por completo
AR107871A1 (es) Combinaciones de inhibidores de lsd1 para su uso en el tratamiento de tumores sólidos
CL2022000194A1 (es) Uso para tratar la enfermedad de hemorragia alveolar difusa asociada con trasplante de células madre hematopoyéticas (divisional de la solicitud no. 202000384)
UY38999A (es) Degradadores de proteína tirosina fosfatasa y métodos de uso de los mismos
CO2022004902A2 (es) Anticuerpo anti beta-amiloide para el tratamiento de la enfermedad de alzheimer
CO2022013167A2 (es) Composiciones y métodos para tratar o prevenir enfermedades inflamatorias que incluyen diabetes mellitus tipo i y tipo ii y enfermedades de la tiroides
CL2021001623A1 (es) Terapia de combinación con un inhibidor de raf y un inhibidor de cdk4/6 para utilizar en el tratamiento del cáncer
EA202090564A1 (ru) Способы усиления и/или стабилизации сердечной функции у пациентов с болезнью фабри
CO2020006924A2 (es) Implantes de liberación sostenida para bajar la presión intraocular con duración extendida del efecto
CL2021000924A1 (es) Uso de reboxetina para el tratamiento de narcolepsia
CO2021015130A2 (es) Péptidos bnip3 para el tratamiento de la lesión por reperfusión
ECSP20055797A (es) Métodos y composiciones para tratar enfermedades pulmonares crónicas
CO2022016153A2 (es) Inhibidores de il4i1 y métodos de uso
CL2022000790A1 (es) Método para tratar vih con cabotegravir y rilpivirina